{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:42:11Z","timestamp":1787971331148,"version":"build-2784847793"},"reference-count":171,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life\u2010threatening systemic, inflammatory disease with multi\u2010organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type\u20102 immune response driving predominantly eosinophilic inflammation, B\u2010cell mediated autoimmunity, neutrophil activation, and the generation of pathogenic anti\u2010neutrophil cytoplasmic antibodies, all of which can contribute to tissue\/organ damage. High\u2010dose glucocorticoids are the mainstay treatment for EGPA, but over the past two decades the development of biologic treatments targeting interleukin (IL)\u20105, eosinophils and B\u2010cells has revitalized the treatment landscape. Mepolizumab, a humanized monoclonal antibody that specifically targets IL\u20105, and benralizumab, which targets the IL\u20105 receptor (IL\u20105R\u03b1), are both approved for the treatment of patients with non\u2010severe relapsing or refractory EGPA. In Phase III trials, these biologics have demonstrated favorable safety profiles and efficacy, with treatment leading to remission induction, remission maintenance, and oral glucocorticoid sparing benefits. However, as understanding of the full complexity of EGPA pathogenesis improves, new treatment targets are emerging. Consequently, understanding key pathogenic mechanisms at the patient level, enabling a more tailored treatment approach, is an important goal for future research.<\/jats:p>","DOI":"10.1111\/all.70215","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:37:51Z","timestamp":1769164671000},"page":"2775-2791","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice"],"prefix":"10.1111","volume":"81","author":[{"given":"Harold","family":"Wilson\u2010Morkeh","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Seluk","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Critical Care and Sleep Medicine National Jewish Health  Denver Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Bosch","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Thiel","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology Medical University of Graz  Graz Austria"},{"name":"Department of Rheumatology and Clinical Immunology Medical Center\u2014University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology, and Diabetology Medius Klinik Kirchheim, Academic Teaching Hospital, University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2946","authenticated-orcid":false,"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Critical Care and Sleep Medicine National Jewish Health  Denver Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-7870","authenticated-orcid":false,"given":"Salman","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00958-w"},{"issue":"2","key":"e_1_2_12_3_1","first-page":"277","article-title":"Allergic Granulomatosis, Allergic Angiitis, and Periarteritis Nodosa","volume":"27","author":"Churg J.","year":"1951","journal-title":"American Journal of Pathology"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00097-2016"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.12.004"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199901000-00003"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez570"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05783-8"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001198"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.23100430\u201023122023"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa089"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab007"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road104"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2024.16.2.168"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11263"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.06.004"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3280119854"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330806"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.03.003"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102708"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003956"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0150-2021"},{"key":"e_1_2_12_28_1","unstructured":"EMA \u201cMepolizumab (Nucala) Summary of Product Characteristics \u201d accessed October 5 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/nucala\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_29_1","unstructured":"EMA \u201cBenralizumab (Fasenra) Summary of Product Characteristics \u201d accessed October 5 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/fasenra\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24634"},{"key":"e_1_2_12_32_1","unstructured":"FDA FDA Prescribing Information (Fasenra)accessed October 5 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/annals\u20107324\u201003947"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.23100912\u201023122023"},{"issue":"7","key":"e_1_2_12_35_1","article-title":"Retrospective Analysis of the Burden of Illness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Versus Asthma in Commercially Insured US Patients","volume":"15","author":"Bell C. F.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21002"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002033"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100437"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22686"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.03.011"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12515-9"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2010.551796"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2169-7"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.191"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006083"},{"issue":"1","key":"e_1_2_12_46_1","first-page":"18","article-title":"Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Meta\u2010Analysis of 62 Case Reports","volume":"15","author":"Pakbaz M.","year":"2020","journal-title":"Journal of Tehran Heart Center"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001202"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1379611"},{"issue":"103","key":"e_1_2_12_49_1","first-page":"40","article-title":"Employment, Work Disability and Quality of Life in Patients With ANCA\u2010Associated Vasculitides. The EXPOVAS Study","volume":"35","author":"Benarous L.","year":"2017","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.06.008"},{"issue":"2","key":"e_1_2_12_51_1","article-title":"P235\u2009the Diagnostic Journey of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA) in England: A Retrospective Observational Cohort Study","volume":"79","author":"Siddiqui S.","year":"2024","journal-title":"Thorax"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/23743735221143953"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2016.08.004"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2023.02.013"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14620"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1145257"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.957660"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143366"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-022-01039-w"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12088"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MCHD\u20100020\u20102015"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15544"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes171"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627776"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.053"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3341"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00093"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.05.003"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15627"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14297"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.035"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221113"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072049"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.043"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8607657"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12577"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.07.003"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1159\/000327259"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyac006"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13209"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888763"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.4108"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.1737"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-267542"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1089926"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9898-x"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.02.014"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302241"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222776"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215918"},{"issue":"1","key":"e_1_2_12_91_1","first-page":"131","article-title":"Systemic Injection of Products of Activated Neutrophils and H2O2 in Myeloperoxidase\u2010Immunized Rats Leads to Necrotizing Vasculitis in the Lungs and Gut","volume":"151","author":"Heeringa P.","year":"1997","journal-title":"American Journal of Pathology"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4115"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201804-0809OC"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S67264"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41727"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432088"},{"issue":"103","key":"e_1_2_12_97_1","first-page":"27","article-title":"Neutrophil Extracellular Traps Formation in Patients With Eosinophilic Granulomatosis With Polyangiitis: Association With Eosinophilic Inflammation","volume":"35","author":"Natorska J.","year":"2017","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001606"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.155382"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1985.tb01443.x"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1306-0"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225587"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400141R"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxae002"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01621-3"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1310211"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S176026"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.122"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf240"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.181054"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.14030"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70196-9"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40205"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez139"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22679"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103338"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead302"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185880"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04961-w"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.13901874\u201013992019"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.003"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202003-0729LE"},{"key":"e_1_2_12_125_1","unstructured":"EMA \u201cRituximab (MabThera) Summary of Product Characteristics \u201d accessed October 4 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/mabthera\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_126_1","unstructured":"FDA \u201cFDA Prescriping Information (Nucala) \u201d accessed October 5 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125526s007lbl.pdf."},{"key":"e_1_2_12_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.048"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43146"},{"key":"e_1_2_12_129_1","unstructured":"ClinicalTrials.gov \u201cNCT05030155: Study of Mepolizumab\u2010Based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E\u2010Merge) (E\u2010Merge) \u201d accessed November 18 2025 https:\/\/clinicaltrials.gov\/study\/NCT05030155."},{"key":"e_1_2_12_130_1","unstructured":"FDA \u201cFDA Prescribing Information (Rituxan) \u201d accessed November 5 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5467lbl.pdf."},{"key":"e_1_2_12_131_1","article-title":"Long\u2010Term Efficacy of Remission\u2010Induction Regimens for Eosinophilic Granulomatosis With Polyangiitis","volume":"75","author":"Dutertre M.","year":"2023","journal-title":"Arthritis and Rheumatology"},{"key":"e_1_2_12_132_1","article-title":"Maintenance of Remission With Rituximab Versus Azathioprine in Newly Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double\u2010Blind Trial [Abstract]","volume":"77","author":"Pu\u00e9chal X.","year":"2025","journal-title":"Arthritis and Rheumatology"},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41943"},{"key":"e_1_2_12_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.11.004"},{"key":"e_1_2_12_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.1055"},{"key":"e_1_2_12_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road109"},{"key":"e_1_2_12_137_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03097-5"},{"key":"e_1_2_12_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.08.021"},{"key":"e_1_2_12_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.08.005"},{"key":"e_1_2_12_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11571"},{"key":"e_1_2_12_141_1","unstructured":"ClinicalTrials.gov. \u201cNCT03010436: Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study (BITE) \u201d accessed December 16 2024 https:\/\/clinicaltrials.gov\/study\/NCT03010436."},{"key":"e_1_2_12_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70096"},{"key":"e_1_2_12_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.07.027"},{"key":"e_1_2_12_144_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.3759"},{"key":"e_1_2_12_145_1","unstructured":"ClinicalTrials.gov \u201cNCT02807103: Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) \u201d accessed October 4 2025 https:\/\/clinicaltrials.gov\/study\/NCT02807103."},{"key":"e_1_2_12_146_1","unstructured":"ClinicalTrials.gov \u201cNCT04157348: Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA) \u201d accessed November 5 2025 https:\/\/clinicaltrials.gov\/study\/NCT04157348."},{"key":"e_1_2_12_147_1","unstructured":"ClinicalTrials.gov \u201cNCT03164473: Maintenance of Remission With Rituximab Versus Azathioprine for Newly\u2010Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. (MAINRITSEG) \u201d accessed October 4 2025 https:\/\/clinicaltrials.gov\/study\/NCT03164473."},{"key":"e_1_2_12_148_1","doi-asserted-by":"publisher","DOI":"10.3389\/flupu.2024.1479884"},{"key":"e_1_2_12_149_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000453"},{"key":"e_1_2_12_150_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa074"},{"key":"e_1_2_12_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.023"},{"key":"e_1_2_12_152_1","unstructured":"EMA \u201cCinqaero (Reslizumab) Summary of Product Characteristics \u201d accessed October 4 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cinqaero\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.01.035"},{"key":"e_1_2_12_154_1","unstructured":"ClinicalTrials.gov \u201cNCT02947945: Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study (RITE) \u201d accessed December 16 2024 https:\/\/clinicaltrials.gov\/study\/NCT02947945."},{"key":"e_1_2_12_155_1","unstructured":"ClinicalTrials.gov \u201cNCT05263934: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN) \u201d accessed December 16 2024 https:\/\/clinicaltrials.gov\/study\/NCT05263934."},{"key":"e_1_2_12_156_1","unstructured":"ClinicalTrials.gov \u201cNCT05979051: A Study to Evaluate the Efficacy and Safety of SHR\u20101703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis EGPA \u201d accessed December 16 2024 https:\/\/clinicaltrials.gov\/study\/NCT05979051."},{"key":"e_1_2_12_157_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae554"},{"key":"e_1_2_12_158_1","unstructured":"ClinicalTrials.gov \u201cNCT06046222: Trial of Efficacy and Safety of NS\u2010229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis \u201d accessed May 28 2025 https:\/\/clinicaltrials.gov\/study\/NCT06046222."},{"key":"e_1_2_12_159_1","unstructured":"ClinicalTrials.gov \u201cNCT06230354: Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis (RACEMATE) \u201d accessed December 16 2024 https:\/\/clinicaltrials.gov\/study\/NCT06230354."},{"key":"e_1_2_12_160_1","unstructured":"EMA \u201cTezepelumab (Tezepsire) Summary of Product Characteristics \u201d accessed May 28 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/tezspire\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_161_1","unstructured":"FDA \u201cFDA Prescribing Information (Tezspire) \u201d accessed May 28 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761224s000lbl.pdf."},{"key":"e_1_2_12_162_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"e_1_2_12_163_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414482"},{"key":"e_1_2_12_164_1","unstructured":"EMA \u201cDupixent Summary of Product Charactrisitcs \u201d accessed February 14 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/dupixent\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_165_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224756"},{"key":"e_1_2_12_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.05.019"},{"issue":"4","key":"e_1_2_12_167_1","first-page":"386","article-title":"Eosinophilic Complications During Dupilumab Therapy for Type 2 Diseases: A Systematic Review","volume":"63","author":"Lazzeroni M.","year":"2025","journal-title":"Rhinology"},{"key":"e_1_2_12_168_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0823"},{"key":"e_1_2_12_169_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02845-3"},{"key":"e_1_2_12_170_1","doi-asserted-by":"publisher","DOI":"10.5603\/ocp.99957"},{"key":"e_1_2_12_171_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3664-1"},{"key":"e_1_2_12_172_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-5496"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.70215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.70215","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.70215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:06:07Z","timestamp":1786557967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.70215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":171,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/all.70215"],"URL":"https:\/\/doi.org\/10.1111\/all.70215","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}